Recent advances with liposomes as pharmaceutical carriers

By Vladimir Torchilin. Nature reviews. Drug discovery, 2005

4,931 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors (2017, neutral): “20”
PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. (2009, background): “Among these products, liposomal drugs [4] and polymer– drug conjugates [5] are two dominant classes, accounting for the majority of clinically approved products.”
Strategies in the design of nanoparticles for therapeutic applications (2010, background): “Liposomes, which are spherical vesicles with a lipid bilayer membrane structure, can encapsulate both hydrophilic and hydrophobic agents, protecting the cargo (for example small molecule drugs, nucleotides, proteins, imaging agents or radionucleotides) during circulation in the bod”
A review of stimuli-responsive nanocarriers for drug and gene delivery. (2008, background): “The pH-sensitive liposomes are endocytosed in the intact form and fuse with the endovascular membrane as a consequence of the acidic pH inside the endosome, and release its active contents into the cytoplasm [91].”
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics (2009, neutral): “A number of non-viral strategies have been proposed including lipid, polycationic, nanoparticle and peptide-based formulations as reported in this special issue (Morris et al., 2000; Ogris and Wagner, 2002; Järver and Langel, 2004; Torchilin, 2005), but only a subset of these technologies are effici”